drugset / Trial / NCT07793942

A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)

NCT07793942 ↗

Phase 2 Not yet recruiting 480 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Researchers are looking for new ways to treat certain types of advanced solid tumors. Solid tumors are cancers mostly in organs and tissues in the body, not in the blood or other fluids. Advanced means the cancer has spread nearby or to other parts in the body and cannot be removed with surgery. In this trial, researchers want to learn if the trial medicine called MK-2010, given alone or with other treatments, can treat advanced solid tumors. MK-2010 is designed to help the immune system fight cancer. The goals of this trial are to learn: * About the safety of MK-2010 as monotherapy and in combinations and if participants tolerate them. Tolerate means participants will receive trial treatment unless they need to stop it due to health problems. * How many participants who receive MK-2010 as monotherapy and in combination respond to treatment. Respond means the cancer gets smaller or goes away.

Timeline

Start
2026-10-27
Primary completion
2028-09-26
Completion
2030-07-28

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-2010 Unknown — Intravenous
Comparator Pembrolizumab Monoclonal antibody 400 mg Intravenous
Background Belzutifan Small molecule 120 mg Oral
Background Carboplatin Small molecule — Intravenous
Background Cisplatin Other / unclassified — Intravenous
Background Epinephrine Other / unclassified — —
Background Gemcitabine Small molecule — Intravenous
Background Leucovorin Small molecule — Intravenous
Background Levoleucovorin Unknown — Intravenous
Background Nab-paclitaxel Small molecule — Intravenous
Background Oxaliplatin Small molecule — Intravenous
Background Paclitaxel Small molecule — Intravenous
Background Pemetrexed Small molecule — Intravenous
Background fluorouracil Small molecule — Intravenous

Indications